Results 71 to 80 of about 210,319 (126)
Response of Macroprolactinemia to Dopamine Agonists
Endocrinology Research and Practice, 2008 Macroprolactinemia, defined as hyperprolactinemia with a predominance of the big big prolactin (macroprolactin) isoform, is considered idiopathic and poorly symptomatic. Although macroprolactinemia has been considered to be a cause of apparent resistance
Gonca Tamer +3 more
doaj +2 more sources
Neuroprotection by dopamine agonists [PDF]
Journal of neural transmission. Supplementum, 1994 Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents. Recent findings of impaired mitochondrial function, altered iron metabolism and increased lipid peroxidation in the substantia nigra of parkinsonian patients emphasize the significance of oxidative ...
Lange, K. W. +5 more
openaire +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Switching and combining dopamine agonists
Journal of Neural Transmission, 2003Switching from one dopamine agonist to another is common practice in the treatment of patients with Parkinson's disease. This paper describes some ideas on the most practical way to perform switching. In addition, it describes the possibilities of combining various dopamine agonists and discusses pros and cons for doing so.
U Sommer, B Herting
exaly +3 more sources
Dopamine agonists and Parkinson's disease
Clinical Neurology and Neurosurgery, 1984The therapeutic use of dopamine agonists for Parkinson's disease, clinical guidelines for their introduction into antiparkinson regimens, and their range of adverse effects are reviewed. The role played by the dopaminomimetic ergots in elucidating dopamine receptor function, and laboratory methods that identify dopamine agonists, are also examined.
D B Calne
exaly +3 more sources
Switching and combining of dopamine agonists
Journal of Neurology, 2004Dopamine agonists have been proved safe and effective as initial therapy in early stages of Parkinson's disease. Prospective long-term clinical trials demonstrated that initial symptomatic treatment with a dopamine agonist is associated with a significantly reduced risk for motor complications in comparison with levodopa therapy.
Heinz Reichmann
exaly +3 more sources
Seminars in Neurology, 2001
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Journal of Neural Transmission, 2019
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson's disease (PD ...
R, Horowski, P-A, Löschmann
openaire +2 more sources
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson's disease (PD ...
R, Horowski, P-A, Löschmann
openaire +2 more sources
Medical Clinics of North America, 1999
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Neuroprotection and Dopamine Agonists
2004Parkinson’s disease is a neurodegenerative disorder characterized by a progressive loss of the dopaminergic neurons in the substantia nigra pars compacta. Accumulating evidence indicates that apoptosis contributes to the cell death in Parkinson’s disease patients’ brain.
Zvezdan, Pirtosek, Dusan, Flisar
openaire +2 more sources